Abstract
Chelation therapy plays a prominent role in the clinical treatment of metal intoxication. In this paper the principal causes of metal toxicity are exposed, and the chemical and biomedical requisites of a chelating agent are sketched. The chelating agents currently in use for scavenging toxic metal ions from humans belong to few categories: those characterized by coordinating mercapto groups, by oxygen groups, poliaminocarboxylic acids, and dithiocarbamates. Considering that the complex formation equilibria have been studied for less than 50% of chelators in use, some reflections on the utility of stability constants are presented, together with an evaluation of ligands under the stability profile. The competition between endogenous and toxic target metal ions for the same chelating agent is furthermore examined. A thorough examination of stability constant databases has allowed to select, for each toxic metal, the ligands distinguished by the best pMe values. Even though this selection does not consider the biomedical requisites of a chelating agent, it gives a clear picture both of the pMe values that can be attained, and of the most appropriate chelators for each metal ion.
Keywords: Chelating agent, Chelation therapy, Heavy metal, Speciation, Stability constant, Toxic metal.
Mini-Reviews in Medicinal Chemistry
Title:Chelation Therapy for Metal Intoxication: Comments from a Thermodynamic Viewpoint
Volume: 13 Issue: 11
Author(s): Valeria Marina Nurchi, Miriam Crespo-Alonso, Leonardo Toso, Joanna Izabela Lachowicz and Guido Crisponi
Affiliation:
Keywords: Chelating agent, Chelation therapy, Heavy metal, Speciation, Stability constant, Toxic metal.
Abstract: Chelation therapy plays a prominent role in the clinical treatment of metal intoxication. In this paper the principal causes of metal toxicity are exposed, and the chemical and biomedical requisites of a chelating agent are sketched. The chelating agents currently in use for scavenging toxic metal ions from humans belong to few categories: those characterized by coordinating mercapto groups, by oxygen groups, poliaminocarboxylic acids, and dithiocarbamates. Considering that the complex formation equilibria have been studied for less than 50% of chelators in use, some reflections on the utility of stability constants are presented, together with an evaluation of ligands under the stability profile. The competition between endogenous and toxic target metal ions for the same chelating agent is furthermore examined. A thorough examination of stability constant databases has allowed to select, for each toxic metal, the ligands distinguished by the best pMe values. Even though this selection does not consider the biomedical requisites of a chelating agent, it gives a clear picture both of the pMe values that can be attained, and of the most appropriate chelators for each metal ion.
Export Options
About this article
Cite this article as:
Nurchi Marina Valeria, Crespo-Alonso Miriam, Toso Leonardo, Lachowicz Izabela Joanna and Crisponi Guido, Chelation Therapy for Metal Intoxication: Comments from a Thermodynamic Viewpoint, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/13895575113139990077
DOI https://dx.doi.org/10.2174/13895575113139990077 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Current Protein & Peptide Science A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine An Overall Picture of SARS Coronavirus (SARS-CoV) Genome-Encoded Major Proteins: Structures, Functions and Drug Development
Current Pharmaceutical Design HIV-1 Vpr: Regulator of Viral Survival
Current HIV Research Immunological Targets in Inflammation from the Small Molecule Perspective
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Naturally Occurring Calanolides: An Update on Their Anti-HIV Potential and Total Syntheses
Recent Patents on Biotechnology The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy
Current Pharmaceutical Design Endoplasmic Reticulum Stress in Chronic Obstructive Lung Diseases
Current Molecular Medicine The Functional Logic of Cytosolic 5’-Nucleotidases.
Current Medicinal Chemistry The-N-End Rule: The Beginning Determines the End
Protein & Peptide Letters Development and Validation of HPLC Method to Determine Colchicine in Pharmaceutical Formulations and its Application for Analysis of Solid Lipid Nanoparticles
Current Pharmaceutical Analysis Peroxisome Proliferator-Activated Receptor-α Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier
Current Neurovascular Research Structure and Function of Fbxo7/PARK15 in Parkinson's Disease
Current Protein & Peptide Science Molecularly Targeted Therapy in Breast Cancer: The New Generation
Recent Patents on Anti-Cancer Drug Discovery Effect of Environmental Contaminants on Mammalian Testis
Current Molecular Pharmacology Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Current Pharmaceutical Design Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets